The abstract is read at the publisher; the summary is JClub's.
GINA’s 2026 Strategy Report strengthens personalized, iterative asthma care using the Assess-Adjust-Review cycle to improve symptom control and reduce future risk across the lifespan.
- Why it matters: Asthma outcomes depend on accurate diagnosis, ongoing risk monitoring, and minimizing treatment harm, yet care often varies and may miss objective confirmation and modifiable factors.
- What they did: The report recommends ICS-containing therapy for all adults, adolescents, children, and most preschoolers, advises against SABA-only treatment, and prioritizes Track 1 low-dose ICS-formoterol AIR regimens for adults/adolescents.
- The result: It links AIR-based strategies to substantial reductions in severe exacerbations versus SABA-based regimens and adds 2026 updates expanding AIR options, refining severe-asthma and biologic selection, and revising acute management.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.